Kairos Pharma Reports 17.7-Month Median Progression-Free Survival vs. 2 Months In Interim Phase 2 ENV-105 Prostate Cancer Data
Share
Why It Matters
Kairos tested a new prostate cancer medicine on patients. The medicine kept cancer from growing much longer than before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.